The board of directors of CSPC Pharmaceutical Group Limited announced that, as proposed by the National Health Commission of the People's Republic of China and consented by the National Medical Products Administration (the "NMPA") after assessment, the bivalent COVID-19 mRNA vaccine (XBB.1.5+BQ.1) (SYS6006.32) developed by the Group (the "Product") has been included for emergency use in China for the prevention of COVID-19 caused by the infection of SARS-CoV-2. SYS6006.32, targeting the dominant variants represented by XBB.1.5, is a bivalent mRNA vaccine against XBB.1.5 and BQ.1 variants developed by the Group on the foundation of the first generation COVID-19 mRNA vaccine (brand name: Duentai ()), which has also been included for emergency use in China. In the clinical trials, the Product not only induced very high immunogenicity against the dominant variants EG.5 and XBB.1.5, with live virus neutralizing antibody level 48 and 34 times the level before vaccination, and 4.9 and 5.0 times the level induced by Duentai respectively, but also induced broad-spectrum cross-variant immunity against variants including XBB.1.16, BA.5, XBB.2.3, and BA.2.86. This indicates that the Product may provide good protection against the current dominant strains as well as potential prevalent strains in the future.

The Product also had a good safety profile. The types and severity of the most adverse reactions were comparable to Duentai, with no additional risks. The level of the neutralizing antibodies in the elderly group was comparable to the adult group, but with a better safety profile.

This indicates that the Product may provide better protection for the elderly. The Product adopts advanced technology with independent intellectual property rights, with the advantages of achieving higher production capacity, better process reproducibility, scale-up and large- scale production more easily. The Product demonstrates good consistency in product quality, all batches of samples submitted to the National Institutes for Food and Drug Control have passed the required tests.

The Product is stable and can be stored at 2-8°C for a long time. Key raw materials and excipients used in the production, such as core lipids and cap analogs for mRNA preparation, are all manufactured by the Group, while other excipients and key equipment are all domestically sourced, thus no reliance on overseas suppliers in the supply chain.